Powered by
-
LLY Stock Chart
Historical LLY Prices
Eli Lilly Stock Analysis
Rating: Sell
Total Grade: D
Analysis Breakdown
| LLY Stock Grade: | D |
| Fundamental Grade: | B |
| Quantitative Grade: | D |
| LLY Earnings | |
| Earnings Growth: | C |
| Earnings Momentum: | C |
| Earnings Surprises: | B |
| Analyst Earnings Revisions: | B |
| LLY Financial Information | |
| Sales Growth: | C |
| Operating Margin Growth: | C |
| Cash Flow: | B |
| Return on Equity: | C |
Eli Lilly Stock: Weekly View
| This Week: | D |
|---|---|
| Last Week: | D |
| Two Weeks Ago: | D |
LLY Stock predictions, Articles, and Eli Lilly News
- From InvestorPlace
- From the Web
-
ARMO Biosciences Inc Shares Skyrocket on $1.6 B Eli Lilly Deal - May 10, 2018
ARMO Biosciences (ARMO) stock is skyrocketing today on news of a massive $1.60 billion deal that will have Eli Lilly (LLY) acquiring it. Continue…
-
Pfizer Inc. Stock Is Boring But Great for Your Portfolio’s Health - May 1, 2018
Fundamentally PFE is too cheap. So go long on this earnings dip inside a nervous market. Management is proven for decades and is bankable for the future. Continue…
-
Eli Lilly And Co Produced a Monstrous Q1 Beat, But Is It Enough? - April 24, 2018
LLY stock delivered outstanding results for its just released Q1 report, but significant questions about its future direction remain. Continue…
-
5 Drug Stocks Poised to Surpass on Earnings This Quarter - April 17, 2018
The outlook for the upcoming first-quarter results looks bright. Compare Brokers.... Continue…
-
Eli Lilly (LLY) Shares a Strong Sell at $77.02 - March 1, 2018
Eli Lilly (LLY) a Strong Sell at $77.02 based on the most current relative pricing of its shares and analysis. Continue…
-
Why Eli Lilly and Co Stock is Taking a Hit Today - January 31, 2018
Eli Lilly (LLY) stock was hit hard on Wednesday despite it reporting an earnings beat for the fourth quarter of the year. Continue…
-
Why Investors Should Stay Long Eli Lilly and Co Stock - January 24, 2018
LLY stock had a sudden drop on Jan. 22, but Eli Lilly and Co recovered the bulk of its losses, which means bulls can stay long for the time being. Continue…
-
Solid Quant Score Keep Eli Lilly (LLY) a Buy - December 8, 2017
Eli Lilly and Company (NYSE:LLY) is ranked as a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking LLY has had from Portfolio Grader for the last month. Continue…
-
Eli Lilly’s (LLY) Upgraded to Buy - December 1, 2017
Eli Lilly and Company (NYSE:LLY) is one of 134 companies within the Pharmaceuticals GICS industry group, which is in turn part of the 781 company GICS Health Care sector. LLY's market value is $92.5 billion which falls in the top decile in its industry group. Currently, the stock's Portfolio Grader ranking places it 16 among the 134 companies in this industry group, placing it among the leaders; in the top quartile of the sector with a ranking of 132 among the 781 companies in the sector, and number 842 in the nearly 5,000 company Portfolio Grader universe. Continue…
-
Analytics for Quant Score Drive Upgrade of Eli Lilly (LLY) to Buy - November 24, 2017
The current recommendation of Buy for Eli Lilly and Company (NYSE:LLY) is the result of using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. LLY has been upgraded from a Hold to a Buy in the last week. Continue…
